Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and effects of ruxolitinib 1.5% cream with
those of standard moisturizers in people with non-sclerotic chronic cutaneous GVHD.